Market Forecast By Cancer Type (Lung cancer, Prostate cancer, Colon & rectal cancer, Gastric cancer, Others), By End-use (Hospitals, Diagnostic laboratories, Diagnostic imaging centers, Academia, Specialty clinics, Others) And Competitive Landscape
| Product Code: ETC7549476 | Publication Date: Sep 2024 | Updated Date: Dec 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
According to 6Wresearch internal database and industry insights, the India Oncology Market is projected to grow at a compound annual growth rate (CAGR) of 7.8% during the forecast period (2026-2032).
Below mentioned are the evaluation of years-wise growth rate along with key growth drivers:
| Year | CAGR (%) | Growth Drivers |
| 2021 | 4.3 | Expansion of tertiary care cancer hospitals and increased diagnostic reach |
| 2022 | 5.1 | Growing adoption of advanced imaging and pathology services |
| 2023 | 5.9 | Rising prevalence of lifestyle-related cancers and early screening |
| 2024 | 6.6 | Government investment in oncology infrastructure and AI-based diagnostics |
| 2025 | 7.2 | Increasing availability of targeted therapies and precision oncology |
The India Oncology Market report thoroughly covers the market by cancer type and end-use. The market report provides an unbiased and detailed analysis of ongoing market trends, opportunities/high growth areas, and market drivers, which help stakeholders devise and align their market strategies according to the current and future market dynamics.
| Report Name | India Oncology Market |
| Forecast period | 2026-2032 |
| CAGR | 7.8% |
| Growing Sector | Hospitals & Specialty Oncology Clinics |
India Oncology Market is anticipated to record strong growth due to the rising burden of cancer, expanding diagnostic coverage, and rapid adoption of advanced treatment modalities. Apart from this, growing urbanization, change in lifestyle patterns, and increasing geriatric population have led to higher incidence of lung, colorectal, and prostate cancers. Besides, strong government focus on strengthening cancer care under national health missions, along with increasing private sector investments in oncology hospitals and diagnostic imaging centers, is significantly improving treatment accessibility across the country.
Below mentioned are some prominent drivers and their influence to the market dynamics:
| Drivers | Primary Segments Affected | Why it Matters (Evidence) |
| Rising Cancer Incidence | All Cancer Types; Hospitals | Higher disease prevalence directly increases diagnostic and treatment demand. |
| Expansion of Advanced Diagnostics | Diagnostic Imaging; Laboratories | Early and accurate detection improves treatment outcomes and therapy adoption. |
| Growth of Precision Oncology | Medication; Hospitals | Use of targeted and immuno-oncology therapies increases treatment effectiveness. |
| Private Hospital Investments | Hospitals; Specialty Clinics | Corporate hospital chains expand oncology capacity across emerging centres. |
| Government Focus on Cancer Care | All Types; Hospitals & Academia | Public programs augments affordability and access to oncology services. |
India Oncology Market is expected to grow at the CAGR of 7.8% during the forecast period of 2026-2032. Growth is driven by increasing cancer burden, improving diagnostic infrastructure, wider availability of targeted therapies, and continuous government initiatives aimed at strengthening oncology care delivery nationwide. In addition, rising awareness about early cancer screening, expanding insurance coverage for oncology treatments, and increasing private sector participation in specialty cancer hospitals are further supporting India Oncology Market Growth.
Below mentioned are some major restraints and their influence to the market dynamics:
| Restraints | Primary Segments Affected | What This Means (Evidence) |
| Infrastructure Gaps | Diagnostic Imaging; Clinics | Inadequate availability of PET-CT and radiotherapy units in smaller cities. |
| High Cost of Advanced Therapies | Medication; Specialty Clinics | Targeted and immunotherapies remain unaffordable for many patients. |
| Lack of Skilled Oncologists | All Types; Hospitals | Demand-supply gap affects quality and speed of treatment. |
| Delayed Diagnosis | Diagnostic Services; Others | Late-stage detection upsurges treatment complexity and costs. |
| Infrastructure Gaps | Diagnostic Imaging; Clinics | Inadequate availability of PET-CT and radiotherapy units in smaller cities. |
There are various challenges deterring the growth of India Oncology Industry. Key barriers are high treatment costs, inadequate specialized oncology professionals, and regional disparities in healthcare access. In addition to this, delayed diagnosis, limited insurance penetration for advanced cancer therapies, and infrastructure gaps in rural areas continue to restrict optimal treatment outcomes.
The oncology industry of India is experiencing various influential trends such as:
There are various prominent investment opportunities available in the India Oncology Market which includes:
Some leading players operating in the India Oncology Market include:
| Company Name | Sun Pharmaceutical Industries Ltd. |
|---|---|
| Established Year | 1983 |
| Headquarters | Mumbai, India |
| Official Website | Click Here |
Sun Pharma provides a wide and diversified portfolio of oncology drugs, including targeted therapies, hormonal treatments, and specialty medicines, and plays a significant role in improving treatment accessibility.
| Company Name | Dr. Reddy’s Laboratories Ltd. |
|---|---|
| Established Year | 1984 |
| Headquarters | Hyderabad, India |
| Official Website | Click Here |
Dr. Reddy’s focuses on the development and supply of affordable oncology medicines and biosimilars, supporting wider patient access to advanced cancer therapies.
| Company Name | Cipla Ltd. |
|---|---|
| Established Year | 1935 |
| Headquarters | Mumbai, India |
| Official Website | Click Here |
Cipla offers a broad range of chemotherapy agents and supportive oncology drugs, and is actively involved in improving treatment affordability, enhancing patient adherence, and expanding access to essential cancer medicines across tertiary hospitals and regional cancer centers.
| Company Name | Roche India Pvt. Ltd. |
|---|---|
| Established Year | 1967 |
| Headquarters | Mumbai, India |
| Official Website | Click Here |
Roche India supplies advanced oncology medicines, precision therapies, and diagnostic solutions, supporting the adoption of personalized cancer treatment approaches.
| Company Name | Tata Memorial Centre |
|---|---|
| Established Year | 1941 |
| Headquarters | Mumbai, India |
| Official Website | Click Here |
Tata Memorial Centre is a leading cancer research, education, and treatment institution in India, playing a critical role in clinical research, oncology training, and early detection programs.
According to Indian Government Data, several initiatives have been introduced to strengthen oncology care and boost the India Oncology Market Growth. For example, the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) emphasize on early screening and cancer management. Furthermore, Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PM-JAY) provides financial coverage for cancer treatment, while state governments have launched free cancer screening and radiotherapy programs in public hospitals to improve access and affordability.
In the future years, the outlook for the India Oncology Market will remain strong and increasingly resilient, backed by surging investments in precision medicine, unceasing development of advanced diagnostic imaging infrastructure, and wider integration of digital oncology platforms across hospitals and specialty clinics. In addition, sustained government focus on early detection programs, affordable treatment delivery models, capacity building for oncology professionals, and improved insurance coverage is expected to enhance patient access, treatment outcomes, and long-term market growth across both urban and emerging regional healthcare ecosystems.
The report offers a comprehensive study of the subsequent market segments and their leading categories.
According to Mohit, Senior Research Analyst, 6Wresearch, lung cancer dominates the India Oncology Market due to high prevalence linked to smoking, air pollution, and occupational exposure. Rising use of targeted therapies and immunotherapy has further increased treatment adoption for lung cancer patients.
Hospitals are expected to lead the India Oncology Market share owing to advanced diagnostic facilities, availability of multidisciplinary oncology teams, and comprehensive treatment services including chemotherapy, radiotherapy, and surgery.
The report offers a comprehensive study of the subsequent market segments:
| 1 Executive Summary |
| 2 Introduction |
| 2.1 Key Highlights of the Report |
| 2.2 Report Description |
| 2.3 Market Scope & Segmentation |
| 2.4 Research Methodology |
| 2.5 Assumptions |
| 3 India Oncology Market Overview |
| 3.1 India Country Macro Economic Indicators |
| 3.2 India Oncology Market Revenues & Volume, 2022 & 2031F |
| 3.3 India Oncology Market - Industry Life Cycle |
| 3.4 India Oncology Market - Porter's Five Forces |
| 3.5 India Oncology Market Revenues & Volume Share, By Cancer Type, 2022 & 2031F |
| 3.6 India Oncology Market Revenues & Volume Share, By End-use, 2022 & 2031F |
| 4 India Oncology Market Dynamics |
| 4.1 Impact Analysis |
| 4.2 Market Drivers |
| 4.2.1 Increasing prevalence of cancer in India |
| 4.2.2 Technological advancements in oncology treatments |
| 4.2.3 Growing healthcare infrastructure and facilities |
| 4.2.4 Rise in disposable income leading to higher healthcare spending |
| 4.3 Market Restraints |
| 4.3.1 High treatment costs and lack of insurance coverage |
| 4.3.2 Limited access to specialized oncology care in rural areas |
| 4.3.3 Stringent regulatory requirements for new cancer therapies |
| 4.3.4 Shortage of skilled oncology professionals |
| 5 India Oncology Market Trends |
| 6 India Oncology Market, By Types |
| 6.1 India Oncology Market, By Cancer Type |
| 6.1.1 Overview and Analysis |
| 6.1.2 India Oncology Market Revenues & Volume, By Cancer Type, 2022- 2031F |
| 6.1.3 India Oncology Market Revenues & Volume, By Lung cancer, 2022- 2031F |
| 6.1.4 India Oncology Market Revenues & Volume, By Prostate cancer, 2022- 2031F |
| 6.1.5 India Oncology Market Revenues & Volume, By Colon & rectal cancer, 2022- 2031F |
| 6.1.6 India Oncology Market Revenues & Volume, By Gastric cancer, 2022- 2031F |
| 6.1.7 India Oncology Market Revenues & Volume, By Others, 2022- 2031F |
| 6.2 India Oncology Market, By End-use |
| 6.2.1 Overview and Analysis |
| 6.2.2 India Oncology Market Revenues & Volume, By Hospitals, 2022- 2031F |
| 6.2.3 India Oncology Market Revenues & Volume, By Diagnostic laboratories, 2022- 2031F |
| 6.2.4 India Oncology Market Revenues & Volume, By Diagnostic imaging centers, 2022- 2031F |
| 6.2.5 India Oncology Market Revenues & Volume, By Academia, 2022- 2031F |
| 6.2.6 India Oncology Market Revenues & Volume, By Specialty clinics, 2022- 2031F |
| 6.2.7 India Oncology Market Revenues & Volume, By Others, 2022- 2031F |
| 7 India Oncology Market Import-Export Trade Statistics |
| 7.1 India Oncology Market Export to Major Countries |
| 7.2 India Oncology Market Imports from Major Countries |
| 8 India Oncology Market Key Performance Indicators |
| 8.1 Number of oncology clinical trials conducted in India |
| 8.2 Adoption rate of advanced oncology treatments |
| 8.3 Percentage of cancer patients receiving timely diagnosis and treatment |
| 8.4 Investment in oncology research and development |
| 8.5 Patient satisfaction with oncology care services |
| 9 India Oncology Market - Opportunity Assessment |
| 9.1 India Oncology Market Opportunity Assessment, By Cancer Type, 2022 & 2031F |
| 9.2 India Oncology Market Opportunity Assessment, By End-use, 2022 & 2031F |
| 10 India Oncology Market - Competitive Landscape |
| 10.1 India Oncology Market Revenue Share, By Companies, 2022-2032F |
| 10.2 India Oncology Market Competitive Benchmarking, By Operating and Technical Parameters |
| 11 Company Profiles |
| 12 Recommendations |
| 13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here